The drug resistance of the third‐generation EGFR‐TKI osimertinib is a global problem in lung cancer therapy, we then studied the therapeutic potential of GM‐protac in osimertinib‐resistant lung cancer mice. This evidence concerns the gene EGFR and lung cancer.